All In Biotech

Drug Trial Radar · NCT04820049

F573 Ia Clinical Trial

F573 for Injection Phase Ia Clinical Trial.

Last checked: Nov 19, 2026Latest source record: Nov 8, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

100

Actual

Start

Feb 8, 2021

Primary completion

Aug 2, 2022

Study completion Nov 6, 2022

Sponsor

Sponsor type
Industry
First posted
Mar 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Tolerance and PK study of F573

Conditions

  • Tolerance
  • Pharmacokinetic

Interventions

  • F573Drug

    F573 for injection

  • PlaceboOther

    Water for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MTD of F573 in health peopleTime frame: up to 7 days
  2. Cmax of F573 in health peopleTime frame: up to 7 days
  3. Tmax of F573 in health peopleTime frame: up to 7 days
  4. t1/2 of F573 in health peopleTime frame: up to 7 days
  5. AUC of F573 in health peopleTime frame: up to 7 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.